Sensitivity and specificity calculations across the expanded validation panel were consistent with those obtained from the initial panel.
The performance of the assay on the complete validation panel, including carriers of at least one non-addressed allele, is shown in Table S7.
Verification of the new batches of HIV rapid tests and reagents was ensured by testing a batch validation panel prepared by the ICRL.
Using a validation panel of 175 samples from Kampala, Uganda, previously defined by sequence-based typing, the new assay performed with 100% sensitivity and specificity.
Within the validation panel, some of the specimens contained at least one allele not addressed in the current platform (Table S5).
We repeated genomic evaluation with this validation panel and estimated the accuracy of GEBV.
Differential methylation between tumor and adjacent tissue was confirmed in the validation panel.
The validation panel consisted of 173 samples, analysed in 18 GS Junior runs.
Sanger typing results from the validation panel were available for all loci with few exceptions.
These 25 SNPs were reliably scored across the validation panel and thus, were considered true SNPs.
However, these exemptions are indeed rare and could not be identified in our validation panel.
